Primary Dysbetalipoproteinemia: Predominance of a Specific Apoprotein Species in Triglyceride-Rich Lipoproteins
Open accessAbstract
Lipoproteins of very low density that are unusually rich in cholesteryl esters accumulate in blood plasma in a characteristic primary form of human hyperlipoproteinemia. These lipoproteins, which are thought to be products of the initial catabolic step in the metabolism of normal triglyceride-rich lipoproteins, have beta rather than pre-beta mobility on electrophoresis, presumably because they have lost certain protein components from their surface. In this study, we have used polyacrylamide gel electrophoresis of apoprotein components that are soluble in tetramethylurea to show that the very low-density lipoprotein fraction of blood serum from seven patients with hyperlipoproteinemia contains unusually large amounts of an arginine-rich protein. Pre-beta migrating, very low-density lipoproteins separated from serum of post-absorptive patients and chylomicrons obtained after a fat-rich meal contain normal amounts of this arginine-rich protein, but beta-migrating, very low-density lipoproteins and chylomicron-like particles separated from serum of post-absorptive patients contain more than twice as much. These apparently partially degraded lipoproteins also contain more tetramethylurea-insoluble protein and smaller amounts of the other soluble protein components than their normal counterparts.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The E2/2 mutation combined with other genetic or environmental factors affects catabolism of apoE-containing lipoproteins and results in accumulation in plasma of remnants of lipoprotein catabolism.
“This mutation combined with other genetic or environmental factors affects the catabolism of apoE-containing lipoproteins and results in the accumulation in plasma of remnants of lipopro tein catabolism ( 7,11 ).”
From Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4 (2011) · cites this paper as [11]
Cites
EARLY EFFECTS OF FAT INGESTION ON LIPIDS AND LIPO-PROTEINS OF SERUM IN MAN
Havel, R. J. (1957) · Journal of Clinical Investigation · doi:10.1172/jci103491 · Cited by 223 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · see citing works
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701 · see citing works
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830 · see citing works
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800069-jlr200 · Cited by 580 · see citing works
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570 · see citing works
Zannis, V. I., & Breslow, J. L. (1981) · Biochemistry · doi:10.1021/bi00507a059 · Cited by 563 · see citing works
Liu, L., MacKenzie, K. R., Putluri, N., Maletić-Savatić, M., & Bellen, H. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.024 · Cited by 556 · see citing works
Utermann, G., Jaeschke, M., & Menzel, J. (1975) · FEBS Letters · doi:10.1016/0014-5793(75)81125-2 · Cited by 337 · see citing works
Fernandez, C. G., Hamby, M. E., McReynolds, M. L., & Ray, W. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00014 · Cited by 277 · see citing works
The biochemical, clinical, and genetic features of type III hyperlipoproteinemia.
MORGANROTH, J., LEVY, R. I., & FREDRICKSON, D. S. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-158 · Cited by 260 · see citing works
Fainaru, M., Mahley, R. W., Hamilton, R. L., & Innerarity, T. L. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38102-5 · Cited by 156 · see citing works
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125 · see citing works
Remnant lipoproteins as therapeutic targets
Havel, R. J. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200012000-00008 · Cited by 107 · see citing works
Self-citationde Knijff, P., van den Maagdenberg, A. M., Stalenhoef, A. F., Leuven, J. A., Demacker, P. N., Kuyt, L. P., Frants, R. R., & Havekes, L. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115349 · Cited by 100 · see citing works
Stalenhoef, A. F., Malloy, M. J., Kane, J. P., & Havel, R. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112632 · Cited by 70 · see citing works
Self-citationVezeridis, A. M., Drosatos, K., & Zannis, V. I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m008409 · Cited by 11 · see citing works
Fotakis, P., Vezeridis, A., Dafnis, I., Chroni, A., Kardassis, D., & Zannis, V. I. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m048348 · Cited by 4 · see citing works
Hernandez Arriaza, R., Reil, D., Fatuzzo, N., Fu, M., Dai, Y., Fernandez Martinez, D., Jiang, H., Holtzman, D. M., Greicius, M. D., & Khosla, C. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00503 · Cited by 2 · see citing works
- Authors
- Havel, R. J., & Kane, J. P.
- Affiliations
- University of California, San Francisco (US)
- ORCID
- Kane, John P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1973-07
- Volume
- 70
- Issue
- 7
- Pages
- 2015-2019
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC433655
- OpenAlex
- W2028029191
- Cited by
- 231
- References
- 1
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 1 · 2023: 8 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2014: 3
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- U.S. Public Health Service
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- VLDL, triglyceride-rich lipoproteins, chylomicrons, lipoprotein electrophoretic mobility, hyperlipoproteinemia
- MeSH terms
- Amino Acids, Apoproteins, Arginine, Electrophoresis, Polyacrylamide Gel, Humans, Hyperlipidemias, Lipoproteins, Lipoproteins, VLDL, Methane, Triglycerides, Urea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
